Liquidia Draws Bullish View at Raymond James on Yutrepia Potential
Insider Sale: Director Raymond Dwek Sells 5,000 Shares of United Therapeutics Corp (UTHR)
$100 Invested In This Stock 10 Years Ago Would Be Worth $400 Today
H.C. Wainwright Maintains United Therapeutics(UTHR.US) With Buy Rating, Maintains Target Price $400
Express News | United Therapeutics Corp : UBS Cuts Target Price to $365 From $370
Morgan Stanley Downgrades United Therapeutics(UTHR.US) to Hold Rating, Raises Target Price to $337
Oppenheimer Maintains United Therapeutics(UTHR.US) With Buy Rating, Maintains Target Price $400
United Therapeutics Corporation's (NASDAQ:UTHR) Low P/E No Reason For Excitement
Express News | HC Wainwright & Co. Reiterates Buy on United Therapeutics, Maintains $400 Price Target
A Quick Look at Today's Ratings for United Therapeutics(UTHR.US), With a Forecast Between $280 to $400
United Therapeutics (UTHR) Gets a Buy From Oppenheimer
United Therapeutics Is Maintained at Underperform by B of A Securities
United Therapeutics Analyst Ratings
Ladenburg Thalmann Downgrades United Therapeutics to Neutral From Buy, $319 Price Target
Express News | United Therapeutics Corp : BofA Global Research Cuts Price Objective to $280 From $303
Express News | United Therapeutics Corp : Leerink Partners Raises Target Price to $350.00 From $344.00
Decoding United Therapeutics Corp (UTHR): A Strategic SWOT Insight
Top Gap Ups and Downs on Wednesday: MUFG, SMFG, MO and More
United Therapeutics Corporation (UTHR) Q2 2024 Earnings Call Transcript
Express News | United Therapeutics Shares Are Trading Lower After the Company Reported Mixed Q2 Financial Results